Middle East and Africa Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and

Middle East and Africa Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)

The biopharmaceutical contract manufacturing market in Middle East & Africa is expected to grow from US$ 457.89 million in 2021 to US$ 666.06 million by 2028; it is estimated to register a CAGR of 5.5% from 2021 to 2028.

The contract manufacturing organization (CMO) offers many benefits to pharmaceutical companies, including reducing investments in facilities and drug development costs, thereby improving net cash flow. Outsourcing is cheaper and enhances the efficiency of manufacturing processes. It allows pharmaceutical & biotechnology companies to redirect resources to other areas. In the past few years, the contract manufacturing industry was a niche service market offering more manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the rising number of drug manufacturing failures. Pharmaceutical companies undertook many manufacturing facilities to develop innovative drugs in the past. However, the demand for manufacturing outsourcing has continuously risen to reduce the risk of overcapacities. Moreover, several pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, further growing reliance on CMOS for manufacturing. Furthermore, the CMOs are vital in providing additional benefits to mitigate the risk of supply shortages by offering various sites for pharmaceutical companies with multisite supply strategies and backup capacities.

Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation

Middle East & Africa Biopharmaceutical Contract Manufacturing Market - By Product

Biologics Monoclonal Antibodies Recombinant Proteins Vaccines Others Biosimilar Middle East & Africa Biopharmaceutical Contract Manufacturing Market - By Service

Process Development Downstream Processing Upstream Processing Fill and Finish Operation Analytical and QC Studies Packaging

Middle East & Africa Biopharmaceutical Contract Manufacturing Market - By Source

Mammalian Microbial-Based Biologics/ Non-Mammalian

Middle East & Africa Biopharmaceutical Contract Manufacturing Market- By Country

The UAE Saudi Arabia South Africa The Rest of Middle East & Africa Middle East & Africa Biopharmaceutical Contract Manufacturing Market-Companies Mentioned

Abb Vie Inc. Ajinomoto Co. Inc Boehringer Ingelheim International Gmb H General Electric Company Lonza MERCK KGAA Samsung Biologics THERMO FISHER SCIENTIFIC INC

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA Biopharmaceutical Contract Manufacturing Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA Biopharmaceutical Contract Manufacturing Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the Biopharmaceutical Contract Manufacturing Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution